- Home
- NEXM vs PRPO Comparison
NEXM vs PRPO Comparison
Compare NEXM & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEXM | PRPO |
|---|---|---|
| Founded | N/A | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.1M | 38.3M |
| IPO Year | 2002 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NEXM | PRPO |
|---|---|---|
| Price | $1.20 | $24.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 36.2K | 28.6K |
| Earning Date | 11-24-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1044.00 | 92.15 |
| EPS | ★ 0.63 | N/A |
| Revenue | N/A | ★ $24,049,000.00 |
| Revenue This Year | N/A | $233.72 |
| Revenue Next Year | N/A | $22.61 |
| P/E Ratio | $1.90 | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $1.15 | $17.79 |
| 52 Week High | $4.71 | $33.63 |
Technical Indicators
Market Signals| Indicator | NEXM | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 30.60 | 61.46 |
| Support Level | N/A | $24.09 |
| Resistance Level | $2.39 | $24.78 |
| Average True Range (ATR) | 0.11 | 1.50 |
| MACD | 0.01 | 0.82 |
| Stochastic Oscillator | 7.69 | 83.58 |
Price Performance
Historical ComparisonAbout NEXM NexMetals Mining Corp.
NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.
About PRPO Precipio Inc.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.